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Abstract: Tumor imaging with myocardial
perfusion agents has been a focal point for
researchers. A kinetic study with
99mTechnetium– methoxyisobutylisonitrile
(99mTc–MIBI) was performed to evaluate the
tumor uptake of this radiopharmaceutical in
lung cancer. Thirty–five patients with lung
cancer were studied. In 21 (60%) patients,
there were regions of high uptake of
99mTc–MIBI in the lesions. Heart/tumor
(H/T), heart/lung (H/L) and tumor/lung (T/L)
ratios were obtained. H/T and H/L ratios
were 1.66±0.22 and 2.10±0.28 in 2–3 min,
and 1.69±0.25 and 2.14±0.27 in 29–30
min respectively. The T/L ratio was
1.28±0.10 in 2–3 min and 1.29±0.14 in
29–30 min. While the differences between
H/T and H/L ratios were statistically

Introduction
Evaluation of patients with suspected or known lung
cancer is a part of nuclear medicine practice. Bone scan
for detection of metastatic involvement and
tumor–directed tracers are gaining increasing use in the
assessment of lung cancer. Myocardial perfusion agents,
201
such
as
Thallium
(201TI)
chloride
and
99m
Technetium–methoxyisobutylisonitrile (99mTc–MIBI)
have been under study for determination of their roles in
the detection of tumors (1). 99mTc–MIBI is a more suitable
agent than 201TI chloride because of its superior physical
characteristics such as shorter half–life, better dosimetry
and optimal photon energy peak (2). Another
technetium–labeled myocardial perfusion agent,
Tetrofosmin, has been investigated in tumor detection,
but not enough data is available as greater numbers of
patients are needed (3).
Technetium–99m–MIBI uptake in different tumors
has been demonstrated by many investigators (4–7). One

significant, there were no significant
differences between early and late uptake
ratios. Seventy per cent (7/10) of small cell
and 56% (14/25) of squamous cell cancers
were detected visually. 99mTc–MIBI uptake in
small cell tumors was higher than in
squamous cell tumors. Tumor blood flow was
seen in the systemic phase of the
radiopharmaceutical as the blood supply of
the tumor was the bronchial artery. The
sensitivity of 99mTc–MIBI planar scintigraphy
for lung cancer detection was inadequate,
and the early and delayed ratios revealed that
small cell cancer showed higher 99mTc–MIBI
accumulation than squamous cell cancer.
Key Words: Lung cancer, Technetium –99 m
methoxyisobutylisonitrile, planar scintigraphy

tumor that is known to accumulate 99mTc–MIBI is lung
cancer. Lung cancer is the first leading cause of cancer
death in men, and it consists of four major cell types,
squamous
carcinoma,
small
cell
carcinoma,
adenocarcinoma and large cell carcinoma. This study was
designed to examine 99mTc–MIBI uptake and kinetics in
various lung cancer cell types.
Materials and Methods
Thirty–five patients with lung cancer were studied.
Primary lung cancer was proven by bronchoscopic
biopsies in all of the patients. In all patients, CT and/or
chest X–ray demonstrated a lesion or lesions bigger than
2.5 cm in the lung. Technetium–99m–MIBI study was
performed on all patients before they received any
therapy. A commercial MIBI preparation (Cardio–spect®)
was obtained form FJC National Research Institute for
Radiobiology and Radiohygiene, Budapest, Hungary. An

135

Radioisotopic Evaluation of Malignant Lung Tumors: A Technetium-99M-Methoxyisobutylisonitrile Study

anterior throax dynamic acquisition was performed for
30 min after the i.v. bolus injection of 444–555 MBq of
99m
Tc–MIBI in the supine position, using a gamma camera
with a low–energy all–purpose collimator with a 64x64
matrix, obtaining 2 sec images for 1 min and 1 min
images for the following 29 minutes. The injection site
and its volume were the same in all patients. Regions of
interest (ROIs) were drawn over the lesions, the rest of
the lung and the left ventricle in all patients (Fig 1). Time
activity curves were generated. By assigning ROIs to the
2–3 min and 29–30 min added images of the patients,
the mean counts per pixel were calculated and the uptake
ratios of the heart to the tumor (H/T), the heart to the
lung (H/L) and the tumor to the lung (T/L) were
calculated. These ratios were presented as average ±S.D.
The statistical significance between H/T and H/L was
assessed by Mann–Whitney U test. A Wilcoxon test was
used to determine the statistical significance between
early and late uptake ratios.

EARLY

Figure 1.

Schematic representation of regions of interest. (T: Tumor,
L: Lung, H: Heart).

Results
Technetium–99m–MIBI uptake was demonstrated in
21/35 (60%) of the lung cancer patients qualitatively
(Figures 2 and 3). It was shown that 25 of the patients
had squamous cell cancer and 10 had small cell cancer.
Sevently per cent (7/10) of the small cell and 56%

Table 1.

LATE

NO

HIST.TYPE

H/T

H/L

T/L

H/T

H/T

T/L

1

Squa.Cell

1.61

2.33

1.45

1.66

2.41

1.45

2

“

1.78

2.27

1.28

1.68

2.10

1.25

3

“

1.60

2.18

1.36

1.74

2.30

1.32

4

”

1.59

1.83

1.15

1.57

1.99

1.27

5

“

1.80

2.41

1.34

2.08

2.35

1.13

6

“

1.92

2.86

1.49

1.98

2.90

1.46

7

“

1.98

2.26

1.14

2.22

2.74

1.23

8

“

1.90

2.21

1.16

1.81

2.08

1.15

9

“

1.79

2.15

1.20

1.81

2.18

1.20

10

“

1.74

1.96

1.13

1.68

2.01

1.20

11

“

1.84

2.29

1.24

1.71

2.18

1.27

12

“

1.97

2.05

1.04

1.92

2.03

1.06

13

“

1.58

1.73

1.09

1.57

1.86

1.18

14

“

1.80

1.93

1.07

1.74

2.00

1.22±0.14

1.79±0.19

Mean value ± S.D.

1.77±0.14

1.15
1.24±0.11

15

Small Cell

1.40

1.90

1.36

1.44

1.90

1.32

16

“

1.29

1.96

1.52

1.36

2.12

1.56

17

“

1.60

1.93

1.21

1.67

1.90

1.14

18

“

1.26

1.85

1.47

1.35

2.00

1.48

19

“

1.58

2.31

1.46

1.48

2.27

1.53

20

“

1.38

1.87

1.36

1.51

2.00

1.32

21

“

1.44

1.92

1.33

1.34

1.84

1.42±0.13

1.39±0.10

1.45±0.11

1.66±0.22

2.10±0.28 1.28±0.10

Mean value ± S.D.

Mean value±S.D.
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1.37
1.39±0.15

1.69±0.250 2.14±0.27 1.29±0.14

Histological types and
Tc–99m MIBI uptake ratios.
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Figure 2.

Forty–nine–year–old man
with small cell carcinoma of
the lung. A- Chest X–ray
reveals the lesion in the
upper part of the left lung.
B- 99mTc–MIBI scintigraphy
reveals increased uptake at
the tumor site.

A

B
(14/25) of the squamous cell cancers could be detected
visually. Early and late T/L uptake ratios were 1.28±0.10
and 1.29±0.14 respectively. The difference was not
significant (P>0.05). The early and late uptake ratios
were 1.66±0.22 and 1.69±0.25 in tumors (H/T), and
2.10±0.28 and 2.14±0.27 in the rest of the lung (H/L),
respectively. While the differences between tumor and
lung uptake ratios were significant (P<0.01), no
significant differences were found between early and late
uptake ratios in tumors and lungs (Table 1). The early
H/T ratio for squamous cell tumors was 1.77±0.14 and
1.42±0.13 for small cell tumors. The late H/T ratio for
squamous cell tumors was 1.79±0.19 and 1.45±0.11
for small cell tumors. In small cell tumors, early and late

99m

Tc–MIBI uptake were higher than in squamous cell
tumors, and the differences were significant (P<0.01).
The differences between early and late ratios in each
tumor type were not significant (P>0.05). There was no
washout of 99mTc–MIBI in the tumor between 3 and 30
min of the study. Time activity curves showed that the
peak activity was within the first minute. We also
observed in patients that the blood flow of the lesion
occured later than the flow of lung (Figure 4).
Discussion
The search to detect malignant tumors with
radiopharmaceuticals has been continuous, but to date no
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Figure 3.

effective
compound
has
been
available.
Technetium–90m–MIBI has ben reported to accumulate
in tumors. Although the tumor uptake mechanism is not
clearly defined, possible factors that affect 99mTc–MIBI
uptake by tumors are cell membrnae potential,
mitochondrial content, increased tumor blood flow and
capillary permeability (8, 9, 10). Piwnica–Worms et al.
reported that P–glycoprotein (Pgp) activity plays a major
role in 99mTc–MIBI accumulation in cells (11). Pgp is a
transmembrane protein, encoded for by the multidrug
resistance gene. This protein transports many
chemotherapeutic agents, such as doxorubicin, out of
cells. One of the mechanisims of the resistance of
malignant tumors to chemotherapy is related to the level
of pgp, increased levels of which are found in tumor
biopsies from relapsing cancer patients. Accumulation of
99m
Tc–MIBI in cells is inversely proportional to the level of
pgp. Functional imaging of tumors with 99mTc–MIBI may
provide important information about the pgp status of
tumors.
Hassan et al. demonstrated that the maximum
Tc–MIBI accumulation in tumors occurs within one
minute (4). The optimum time for imaging following
injection of 99mTc–MIBI has been reported as being
between 10 and 60 min (12). There have been reports in
the literature on the use of 99mTc–MIBI for differentiating
benign from malignant lung tomurs. In these studies, the
sensitivity of 99mTc–MIBI for detecting primary lung
cancer was within 65%–96% (13–15). The specificity
was not high because of 99mTc–MIBI uptake in some
benign lesions (12, 16). Some investigators have found a
99m
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Fifty–five-year-old man with
squamous cell carcinoma of
99mTc-MIBI
the
lung.
scintigraphy
reveals
doughnut-like uptake in the
upper part of the left lung
due to necrosis in the
center of the tumor.

relationship between the accumulation of tumor
researching tracers (67Ga and 201TI) in lung tumors and
the histological type of the tumor, but others have shown
no relationship (12).
In our patients, the results of the dynamic study
showed an early peak (within one minute) in all tumor
regions due to the increased blood flow. Factors that
affect the height of this peak, such as the injection site
and its volume, were the same in all patients. We also
observed that the tumors presented different flow
patterns in the first minute of the study. Tumor blood
flow was not seen in the pulmonary phase, but it was
seen in the systemic phase of the radiopharmaceutical.
This is possibly due to the fact that lung tumors receive
their blood supply from the bronchial arteries. We found
no difference in tumor uptake ratios between 3 and 30
min. This finding showed that there was no significant
tumor washout of 99mTc–MIBI. We detected lung cancer
foci in 60% of our patients qualitatively, which were
confirmed quantitatively. The degree of 99mTc–MIBI
accumulation in the malignant lung tumors differed in
each histological type. 99mTc–MIBI uptake in small cell was
higher than in squamous cell tumors.
The sensitivity of 99mTc–MIBI for lung cancer detection
was inadequate. Uptake of this radiopharmaceutical may
vary according to the histological type of the lung cancer.
Many studies have indicated that uptake of 99mTc–MIBI
could permit the prediction of the response to the
chemotherapy, when the decreased accumulation of
99m
Tc–MIBI implies the presence of pgp–associated drug
resistance.
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Figure 4.

Forty–nine–year-old woman
with small cell carcinoma of
the lung. A- First phase of the
dynamic study reveals that
tumor perfusion is in the
same phase as the systemic
flow (between arrowheads).
B- 2-3 min. added frame of
the same study reveals
increased 99mTc-MIBI uptake
in the lower part of the right
lung
and
pericardial
hypoactivity
due
to
pericardial effusion. C-CT
scan
of
the
patient
demonstrates the tumor in
the posterior region of the
right lung with atelectasis in
the anterior region.

A

B

C
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